Research programme: ghrelin receptor antagonists - AEterna ZentarisAlternative Names: 1,2,4-Triazole based ghrelin receptor ligands as anti-obesity agents - AEterna Zentaris; AEZS-123; JMV 2760; JMV 2959; JMV 3018; JMV 3534
Latest Information Update: 14 May 2012
At a glance
- Originator Zentaris
- Developer AEterna Zentaris GmbH; AEterna Zentaris Inc; University of Milan; University of Montpellier I; University of Montpellier II; University of Montreal
- Class Small molecules; Triazoles
- Mechanism of Action Ghrelin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Obesity
- No development reported Alcoholism